Linkedin X-twitter Youtube
Launch Digital Edition

Webinars and Sponsored Roundtables — Register Now

Tuesday, April 28, 2026, 12:00 PM–1:00 PM ET
Discover how next-day comprehensive genomic profiling (CGP) is possible with the Oncomine Comprehensive Assay Plus on the Genexus System—delivering both speed and accuracy.

Webinar presenters Jane Bayani, MHSc, PhD, Assistant Professor and Co-Director, Diagnostic Development, Ontario Institute for Cancer Research, Canada, and Nicola Normanno, MD, Scientific Director, IRCCS Romagnolo Institute for the Study of Tumors, Italy, and Morten Grauslund, PhD, Molecular Biologist, Department of Pathology, Rigshospitalet/Copenhagen University Hospital, Copenhagen, Denmark.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Thermo Fisher Scientific. For Research Use Only. Not for use in diagnostic applications. 

Register Now

Thursday, April 30, 2026, 11:00 AM–12:00 PM ET
Hear an expert discuss how Memorial Sloan Kettering Cancer Center (MSKCC) is utilizing
the oncoReveal® Nexus 21-gene panel to redefine turnaround time and actionable insights
in cancer care. Dr. Ewalt shares a perceptive look at the clinical need for rapid, front-line NGS sequencing, and how a unique, purpose built targeted NGS panel (Pillar Biosciences’ oncoReveal Nexus 21 gene Panel) was developed, validated and implemented clinically by Memorial Sloan Kettering Cancer Center (MSK-REACT) to complement their current comprehensive genomic profiling (CGP) approach.

Webinar presenter Mark Ewalt, MD, Associate Medical Director for Laboratory Operations for Diagnostic Molecular Pathology in the Molecular Diagnostics Service, Department of Pathology and Laboratory Medicine, MSKCC.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Pillar Biosciences.

Register Now

Thursday, May 28, 2026, 1:00–2:00 PM ET
This session is designed to improve understanding and application of recent updates to synoptic pathology reporting protocols such as the latest Reporting Template for Reporting Results of Biomarker Testing of Specimens from Patients with Carcinoma of the Breast. These changes reflect evolving clinical guidelines that directly influence diagnostic accuracy and treatment selection in breast cancer care.

Webinar presenters Thaer Khoury, MD, FCAP, Chair, Pathology and Laboratory Medicine, Roswell Park Comprehensive Cancer Cente, and Colin Murphy,  CEO of mTuitive.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Subspecialties

Interactive Product Guides

Marketplace

Trovagene, Boreal Genomics strategic partnership, 2/17

February 2017—Trovagene has entered into a long-term supply and distribution agreement with Boreal Genomics in which they will merge their respective technologies to co-develop urine and blood ctDNA assay kits. The companies intend to address an unmet need in the liquid biopsy testing market by providing a simple, routine, and low-cost urine and blood ctDNA assay for next-generation sequencing platforms run by laboratories of research institutions, cancer centers, and service facilities around the world.

ARUP Labs, ASI enter collaboration, 2/17

February 2017—Applied Spectral Imaging has entered into a collaboration with ARUP Laboratories to facilitate the development and commercialization of advanced digital pathology solutions, enhancing workflow efficiencies and simplifying the management and accessibility of clinical data.

Fully automated IHC multiplexing kits, 2/17

February 2017—PerkinElmer’s Opal Multicolor Immunohistochemistry products for use with Leica Biosystems’ fully automated Bond RX research staining platform is now available. The kits can visualize up to six biomarkers and a nuclear counterstain on a single tissue section with next-day results.

FDA clears Vitros automation solutions, 1/17

January 2017—Ortho Clinical Diagnostics announced that the Food and Drug Administration has cleared its Vitros Automation Solutions for use with Ortho’s Vitros chemistry, immunodiagnostics, and integrated systems.

Single-cell analysis instrument, 1/17

January 2017—Qiagen launched its QIAscout, a novel instrument for isolation of viable single cells from samples to enable single-cell analysis for next-generation sequencing, polymerase chain reaction, and other downstream applications.

Selective and differential medium, 1/17

January 2017—Hardy Diagnostics announced its new product, C Diff Banana Broth, which is recommended as a selective detection broth for the recovery of Clostridium difficile from environmental samples. Its name is derived from the color change reaction when C. diff is present; the broth changes from a deep red, indicating a negative reaction, to a milky yellow, indicating a positive reaction.

Clariom assays, 1/17

January 2017—Thermo Fisher Scientific’s two Clariom brand of assays, Clariom D Pico and Clariom S Pico, are designed primarily for translational researchers to accelerate the discovery and validation of complex biomarker signatures derived from coding and noncoding RNA across the whole transcriptome. Based on industry-leading microarray technology, the Clariom Pico assay designs include up-to-date content curated from a large number of public sequence databases, including RefSeq, Noncode, Ensembl, VEGA, lncRNAWiki, and RNA Central, among others.

iSpecimen, TriCore collaboration, 1/17

January 2017—iSpecimen and TriCore Reference Laboratories announced an agreement through which iSpecimen will serve as a TriCore channel partner for making patient biospecimens and associated data available for research. iSpecimen’s cloud-based technology will be used to tap into the flow of patients, specimens, and data running through the TriCore organization, matching researchers with a variety of annotated, de-identified samples.

Enzo launches two assays, 1/17

January 2017—Enzo Life Sciences introduced the PlaqPro Lp-PLA2 assay, a colorimetric readout assay that measures the activity of Lp-PLA2 in serum samples. The assay is designed to run on automated chemistry analyzers. Included in the kit are ready-to-use calibration standards and QC controls in order to measure a wide analytical range of 0.0–400.0 nmol/min/mL of Lp-PLA2 activity.

Biotheranostics, Syapse collaboration, 1/17

January 2017—Biotheranostics and Syapse plan to integrate data from Biotheranostics’ CancerType ID and Breast Cancer Index genomic tests into the Syapse Precision Medicine Platform. The software-based service is part of Syapse’s global partner program, which aims to leverage strong collaborators toward an integrative approach to precision medicine.

MARKETPLACE

TRENDING